The Compounding Pharmacy Crackdown: Who's Still Operating and Why

The March 2026 enforcement wave didn't end all compounding. Personalized 503A compounding continues for patients with documented clinical need. Here's who is still operating and under what rules.

The March 2026 FDA warning letters didn't shut down every compounding pharmacy that touches GLP-1s. They didn't even shut down every compounding pharmacy that was named in a letter. The regulatory reality that emerged is more nuanced: mass-production of essentially-copy compounded semaglutide and tirzepatide is functionally over, but personalized 503A compounding for patients with documented clinical need remains legal and active.

Sorting who's still operating — and under what rules — requires understanding the distinction between 503A personalized compounding and 503B outsourcing-facility compounding. Those two legal regimes cover different activities and survived the enforcement wave very differently.

503A vs. 503B: The Distinction That Matters

503A compounding is what most people think of when they hear "compounding pharmacy": a licensed pharmacy compounds a specific medication for a specific patient based on a documented clinical need that the commercially-available product cannot meet. That activity is regulated by state boards of pharmacy and has always been legal for GLP-1s, and continues to be.

503B outsourcing facilities are federally-regulated manufacturing operations that can produce compounded drugs in anticipation of prescriptions — but only under specific exceptions. The most important exception for GLP-1s was the shortage exception, which expired when the FDA declared the shortages resolved.

Who Was Named vs. Who Wasn't

The March 3, 2026 warning letters targeted a specific subset of the compounding ecosystem: telehealth brands marketing compounded GLP-1s as essentially-copy alternatives to Wegovy and Zepbound, 503B facilities that had continued mass-producing after the shortage resolution, and pharmacies selling novel formulations (oral, sublingual, nasal) that were never within the shortage exception.

Pharmacies operating under 503A for individual patients with documented clinical need — allergies to inactive ingredients, pediatric dose requirements, specific clinical circumstances — were not the target. Some of them continue to compound GLP-1s for appropriate patients, and their activity is not affected by the enforcement wave.

The Telehealth Pivot Pattern

Most of the telehealth brands that had been distributing compounded GLP-1s at scale have pivoted rather than shut down. The dominant pattern is a partnership with NovoCare or LillyDirect to distribute brand-name Wegovy or Zepbound at authorized cash-pay prices. Hims, Ro, LifeMD, WeightWatchers, and Sesame Care all operate primarily on this model as of April 2026. A handful of smaller brands maintained compounded distribution through licensed 503A relationships — typically with narrower patient populations and stricter clinical documentation.

A third group — the smallest — exited the GLP-1 category entirely or pivoted to other therapeutic areas. For patients, the practical question is which of those three paths a given provider is on and what that means for their continuity of care.

How to Verify Your Provider's Status

Patients on compounded GLP-1s should ask their provider three direct questions. First, is the medication being compounded under 503A (personalized for me) or 503B (mass-produced)? Second, if 503A, what is the documented clinical need that makes the brand-name product unsuitable? Third, what is the licensed compounding pharmacy's name and state of licensure?

A legitimate 503A operation will answer all three questions without hesitation. A provider that dodges these questions or becomes evasive is signaling a problem.

The Survivors and the Settlers

Looking at the post-March 2026 landscape, three categories of legitimate GLP-1 distribution have emerged. Brand-name authorized telehealth dominates the cash-pay market at $249-349/month. Retail pharmacy cash-pay (Costco, Walmart) covers the self-insured market at ~$499. And personalized 503A compounding fills the narrow clinical gaps — specific allergies, unique clinical needs — at prices that vary by pharmacy. See our full breakdown of the FDA warning letters and fact check on compounded tirzepatide's legal status for deeper context.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.